Glenmark Life Sciences Limited (BOM: 543322)

Market Cap	124.16B
Revenue (ttm)	22.05B
Net Income (ttm)	4.24B
Shares Out	n/a
EPS (ttm)	34.46
PE Ratio	29.32
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,341
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	639.30 - 1,335.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Glenmark Life Sciences

Glenmark Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company’s APIs are used in various therapeutic segments, ...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2011
• Employees: 2,014
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543322

Financial Performance

In 2023, Glenmark Life Sciences's revenue was 22.83 billion, an increase of 5.64% compared to the previous year's 21.61 billion. Earnings were 4.71 billion, an increase of 0.84%.